Evercore ISI analyst Joshua Schimmer downgraded Avidity Biosciences to In Line from Outperform with a $20 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RNA:
- Avidity Biosciences provides regulatory update on dystrophy candidate AOC 1001
- Avidity Biosciences reports Q4 EPS (88c), consensus (89c)
- Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
- Avidity Biosciences advances RNA programs, expands into new therapeutic areas
- Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James